Aurinia Pharmaceuticals Inc.'s SEC filings document the formal reporting record for a Canada-incorporated biopharmaceutical company commercializing LUPKYNIS and developing autoimmune-disease therapies. 8-K filings furnish operating and financial results, product revenue, license, collaboration and royalty revenue, research and development spending, guidance-related exhibits and other material-event disclosures.
The filings also cover proxy governance, executive appointments and compensatory arrangements, shareholder voting matters, capital-structure disclosures, share repurchase activity and material agreements. Recent transaction records include completed acquisition activity, tender-offer and merger mechanics, and contingent value right terms.
Aurinia Pharmaceuticals Inc. director Jeffrey Allen Bailey received a grant of stock options as part of his compensation. The award covers 23,931 options to purchase common shares at an exercise price of $15.67 per share. These options vest one year from the grant date and expire on June 4, 2036. Following this grant, Bailey holds 23,931 options directly, with no open-market purchases or sales reported in this filing.
AUPH Form 144 filing reports proposed and recent transactions in Common stock tied to option exercises and sales. The filing lists a planned sale tied to an Exercise of Options Under a Registered Plan dated 06/05/2026 and two reported sales by Gregory Keenan: 25,000 shares on 06/04/2026 for $408,435.00 and 25,000 shares on 06/02/2026 for $54,100,000.00.
Tang Capital Management, Kevin Tang and affiliated entities amended their Schedule 13D to update their stake in Aurinia Pharmaceuticals Inc. The reporting group now beneficially owns 13,044,106 common shares, representing 10.0% of Aurinia’s outstanding common shares, based on 129,991,655 shares outstanding as of June 3, 2026.
The filing confirms Kevin Tang as Aurinia’s Chief Executive Officer and a board member, and describes multiple Tang Capital vehicles sharing voting and dispositive power over the position. The group also has potential obligations to purchase 1,000,000 additional common shares under put option contracts expiring on January 15, 2027 with a strike price of $15.00 per share, highlighting further potential exposure to Aurinia’s equity.
Aurinia Pharmaceuticals Inc. reported the results of its 2026 annual general meeting, held virtually. Shareholders elected Kevin Tang, Jeffrey Bailey, Kathy Goetz, Craig Johnson and Tina S. Nova to the board of directors, with support for each nominee ranging from 86.50% to 96.59% of votes cast.
Shareholders also approved the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm, with 89.14% of votes cast in favor. In addition, they approved, on a non-binding advisory basis, the company’s executive compensation in a “say on pay” vote, with 93.10% of votes cast supporting the resolution.
Morgan Stanley Smith Barney LLC filed a Form 144 relating to Common shares of AUPH, reporting an exercise of options and proposed sale of 25,000 shares on 06/04/2026.
The filing also records a sale by Gregory Keenan of 25,000 shares on 06/02/2026 with a reported amount of $54,100,000.00. The method of payment for the 06/04/2026 transaction is listed as Cash.
Aurinia Pharmaceuticals Inc. insider entities associated with Chief Executive Officer Kevin Tang reported significant open-market buying of common shares and new derivative positions. Funds managed through Tang Capital partnerships bought a net 814,606 common shares in late May and early June at prices around $15 per share, bringing their indirect holdings to 13,044,106 shares.
In a separate move, Tang-affiliated funds sold 10,000 short put options, creating a potential obligation to acquire up to 1,000,000 additional common shares at $15 per share if exercised by January 15, 2027. Together, these transactions increase the funds’ equity exposure to Aurinia while adding conditional future buying commitments.
AUPH submitted a Form 144 notice for the proposed sale of 25,000 shares of Common Stock on 06/02/2026 tied to an exercise of options under a registered plan. The transaction is reported as an issuer-directed sale with cash proceeds.
Robertson Stephen P. reported acquisition or exercise transactions in this Form 4 filing.
Aurinia Pharmaceuticals Inc. reported that its Chief Legal Officer, Stephen P. Robertson, received an equity compensation award in the form of 115,541 performance stock units. These units were granted at no cash cost per unit and increase his direct holdings to 621,402 common shares or share-based units reported in this filing.
The footnote explains that each performance stock unit represents a contingent right to receive one common share of Aurinia. The 115,541 units vest in two tranches on the third and fifth anniversaries of the grant date, only if Aurinia’s common shares reach target prices that represent significant increases from the grant-date share price before each vesting date.
Hearne Michael S reported acquisition or exercise transactions in this Form 4 filing.
Aurinia Pharmaceuticals Inc. reported that Chief Financial Officer Michael S. Hearne received new equity compensation awards. He was granted 116,144 performance stock units, each representing a contingent right to receive one common share, and 70,230 employee stock options.
The PSUs vest in multiple tranches based on Aurinia’s share price performance and time-based conditions, while the options have a strike price of $15.28 per share and expire on May 18, 2036. These are compensation-related grants rather than open-market share purchases or sales.
Aurinia Pharmaceuticals Inc. reported that Chief Operating Officer Ryan Cole received new equity awards. He was granted 116,144 performance stock units, each representing a contingent right to receive one common share, with vesting tied to share-price targets and time-based conditions. He also received an option grant for 70,230 shares of common stock at an exercise price of $15.28 per share, expiring in 2036. These awards are compensation-related grants, and no open-market share purchases or sales were reported in this filing.